Angela Merkel Says She Will Take AstraZeneca Vaccine Amid Clot Scare
Angela Merkel's firm endorsement of the vaccine came after its use was suspended for several days this week by major European countries over fears that it may cause blood clots.
Chancellor Angela Merkel said Friday that she was ready to be vaccinated with AstraZeneca's coronavirus jab if offered when it is her turn to be inoculated.
"Yes I would take the AstraZeneca vaccine," she told journalists at a news conference, adding however she "would like to wait until it's my turn but I would in any case".
Merkel's firm endorsement of the vaccine came after its use was suspended for several days this week by major European countries, including Germany, over fears that it may cause blood clots.
Europe's medicines regulator EMA on Thursday cleared it for use after a review of the clotting cases, saying the vaccine was "safe and effective".
But questions surrounding the jab jointly developed by AstraZeneca and the University of Oxford were revived when France on Friday recommended it should be given only to people aged 55 and over because of the clotting risks.
Germany on Friday resumed use of the Anglo-Swedish company's jabs, and politicians have taken pains to assure the population of the vaccine's safety.
Winfried Kretschmann, state premier of Baden-Wuerttemberg, got an AstraZeneca jab live on television.
"Have trust, get vaccinated," he said in an appeal to the population.
AstraZeneca has faced a series of setbacks since it was approved for use in the European Union.
Besides delivery delays that angered the bloc, Germany had in the initial weeks of its use limited it to people under 65-years-old because of insufficient efficacy data for older people.
Critics had complained that the decision to halt use of AstraZeneca's vaccine over the recent days because of clotting risks only served to fuel more mistrust over the jabs and further delay Germany's already sluggish inoculation programme.
"Yes I would take the AstraZeneca vaccine," she told journalists at a news conference, adding however she "would like to wait until it's my turn but I would in any case".
Merkel's firm endorsement of the vaccine came after its use was suspended for several days this week by major European countries, including Germany, over fears that it may cause blood clots.
Europe's medicines regulator EMA on Thursday cleared it for use after a review of the clotting cases, saying the vaccine was "safe and effective".
But questions surrounding the jab jointly developed by AstraZeneca and the University of Oxford were revived when France on Friday recommended it should be given only to people aged 55 and over because of the clotting risks.
Germany on Friday resumed use of the Anglo-Swedish company's jabs, and politicians have taken pains to assure the population of the vaccine's safety.
Winfried Kretschmann, state premier of Baden-Wuerttemberg, got an AstraZeneca jab live on television.
"Have trust, get vaccinated," he said in an appeal to the population.
AstraZeneca has faced a series of setbacks since it was approved for use in the European Union.
Besides delivery delays that angered the bloc, Germany had in the initial weeks of its use limited it to people under 65-years-old because of insufficient efficacy data for older people.
Critics had complained that the decision to halt use of AstraZeneca's vaccine over the recent days because of clotting risks only served to fuel more mistrust over the jabs and further delay Germany's already sluggish inoculation programme.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
